Hypercalcemia
Normal total serum calcium:
- Approximately 8.5–10.5 mg/dL (2.1–2.6 mmol/L)
- Ionized calcium >1.32 mmol/L
|
Severity |
Serum Calcium |
|
Mild |
10.5–11.9 mg/dL |
|
Moderate |
12–13.9 mg/dL |
|
Severe |
≥14 mg/dL |
Calcium Physiology
About 99% of body calcium is stored in bone.
Serum calcium exists in 3 forms:
- Ionized (free) calcium (~50%)
- Physiologically active form
- Protein-bound calcium (~40%)
- Mainly albumin-bound
- Complexed calcium (~10%)
- Bound to phosphate/citrate
Corrected Calcium Formula
Low albumin lowers measured total calcium.
Corrected Calcium (mg/dL)=Measured Calcium+0.8×(4−Albumin)
Regulation of Calcium Homeostasis
Major regulators:
- Parathyroid hormone (PTH)
- Vitamin D
- Calcitonin
- Kidney
- Bone
- Gastrointestinal tract
Parathyroid Hormone (PTH)
Actions:
- Increases bone resorption
- Increases renal calcium reabsorption
- Decreases phosphate reabsorption
- Activates vitamin D
Vitamin D
Actions:
- Increases intestinal calcium absorption
- Increases phosphate absorption
- Promotes bone mineralization
Causes of Hypercalcemia
Major Causes
- Primary hyperparathyroidism → most common outpatient cause
- Malignancy → most common inpatient cause
Classification by PTH Level
PTH-Dependent Hypercalcemia
PTH elevated or inappropriately normal.
- Primary hyperparathyroidism(Single parathyroid adenoma)
- Tertiary hyperparathyroidism
- Familial hypocalciuric hypercalcemia (FHH)
- Lithium therapy
PTH-Independent Hypercalcemia(PTH suppressed)
A. Malignancy-Associated Hypercalcemia
- PTHrP-mediated humoral hypercalcemia
- Osteolytic metastases
- Hematologic malignancies
- Lymphoma (↑ calcitriol)
Common malignancies
- Squamous cell carcinoma lung
- Renal cell carcinoma
- Breast cancer
- Multiple myeloma
B. Vitamin D-Mediated
- Vitamin D intoxication
- Granulomatous diseases
- Sarcoidosis
- Tuberculosis
- Lymphoma
C. Endocrine Causes
- Thyrotoxicosis
- Adrenal insufficiency
- Pheochromocytoma
- Acromegaly
D. Drug-Induced
- Thiazides
- Lithium
- Vitamin A excess
- Calcium antacids
E. Miscellaneous
- Immobilization
- Milk-alkali syndrome
- Paget disease
- Recovery phase rhabdomyolysis
Clinical Features
“Stones, Bones, Groans, Thrones, Psychiatric Overtones”
Renal (“Stones”)
- Polyuria
- Polydipsia
- Nephrolithiasis
- Nephrocalcinosis
- Acute kidney injury
Mechanism:
- Nephrogenic diabetes insipidus
- Renal vasoconstriction
- Volume depletion
Skeletal (“Bones”)
- Bone pain
- Osteoporosis
- Osteitis fibrosa cystica
- Pathological fractures
Gastrointestinal (“Groans”)
- Constipation
- Nausea
- Vomiting
- Abdominal pain
- Pancreatitis
- Peptic ulcer disease
Neurologic/Psychiatric
- Fatigue
- Weakness
- Confusion
- Depression
- Cognitive dysfunction
- Delirium
- Coma
Cardiovascular
- Hypertension
- Arrhythmias
- Bradycardia
- Shortened QT interval
- Heart block
ECG Findings
Characteristic finding:
- Short QT interval
Other findings:
- PR prolongation
- Widened QRS
- Heart block
Hypercalcemic Crisis
Defined as:
- Severe symptomatic hypercalcemia
- Usually calcium >14 mg/dL
Features:
- Severe dehydration
- AKI
- Altered mental status
- Arrhythmias
This is a medical emergency.
Investigations in Hypercalcemia
|
Investigation |
When to Investigate |
Reason / What It Helps Diagnose |
|
Repeat serum total calcium |
Immediately after first elevated calcium |
Confirms true hypercalcemia and excludes lab error |
|
Ionized calcium |
Hypoalbuminemia, paraproteinemia, critically ill patients, acid-base disorders |
Measures biologically active calcium; confirms true hypercalcemia when total calcium unreliable |
|
Serum albumin |
In all patients with hypercalcemia |
Needed to calculate corrected calcium |
|
Corrected calcium calculation |
When albumin abnormal |
Determines actual calcium status in hypoalbuminemia |
|
ECG |
Moderate/severe hypercalcemia or symptomatic patients |
Detects short QT interval, arrhythmias, AV block |
|
Serum phosphate |
Initial evaluation in all patients |
Low phosphate suggests primary hyperparathyroidism; high phosphate may suggest CKD/tertiary HPT or vitamin D excess |
|
Serum magnesium |
Initial workup |
Magnesium disorders affect PTH secretion and calcium metabolism |
|
Serum creatinine/eGFR |
Initial evaluation in all |
Assesses renal impairment from hypercalcemia or CKD-related hyperparathyroidism |
|
Blood urea nitrogen (BUN) |
Initial evaluation |
Detects dehydration and renal dysfunction |
|
Electrolytes (Na, K, HCO₃) |
Initial evaluation |
Evaluates dehydration, metabolic alkalosis, milk-alkali syndrome |
|
Intact PTH |
After confirming hypercalcemia |
Most important test; differentiates PTH-mediated vs non-PTH-mediated hypercalcemia |
|
24-hour urinary calcium |
Elevated/inappropriately normal PTH |
Differentiates primary hyperparathyroidism from FHH |
|
Calcium-creatinine clearance ratio (CCCR) |
Suspected FHH vs PHPT |
CCCR <0.01 suggests FHH; >0.02 suggests PHPT |
|
25-OH vitamin D |
All patients or suspected vitamin D disorder |
Detects vitamin D deficiency or intoxication |
|
1,25-(OH)₂ vitamin D |
Low PTH with suspected granulomatous disease or lymphoma |
Elevated in sarcoidosis, TB, lymphoma due to extrarenal vitamin D activation |
|
PTH-related peptide (PTHrP) |
Suppressed PTH with suspected malignancy |
Diagnoses humoral hypercalcemia of malignancy |
|
Serum alkaline phosphatase (ALP) |
Bone pain, malignancy, high bone turnover |
Elevated in osteolytic metastases, Paget disease, hyperparathyroidism |
|
SPEP (serum protein electrophoresis) |
Bone pain, anemia, renal dysfunction, elderly patients |
Detects multiple myeloma |
|
UPEP (urine protein electrophoresis) |
Suspected myeloma |
Detects Bence Jones proteins/light chains |
|
Serum free light chains |
Suspected plasma cell dyscrasia |
Improves detection of multiple myeloma |
|
CBC |
Initial evaluation or malignancy suspicion |
Detects anemia, leukocytosis, hematologic malignancy |
|
ESR/CRP |
Suspected inflammatory disease or myeloma |
Elevated in infection, malignancy, inflammatory disorders |
|
TSH and thyroid profile |
Symptoms/signs of hyperthyroidism |
Hyperthyroidism can cause mild hypercalcemia via increased bone turnover |
|
Morning cortisol / ACTH stimulation test |
Suspected adrenal insufficiency |
Addison disease may cause mild hypercalcemia |
|
Serum ACE level |
Suspected sarcoidosis |
May support diagnosis of sarcoidosis |
|
Chest X-ray |
Smokers, malignancy suspicion, granulomatous disease |
Detects lung cancer, TB, sarcoidosis |
|
CT chest/abdomen/pelvis |
Suspected occult malignancy |
Identifies hidden cancers causing hypercalcemia |
|
PET-CT |
Unexplained malignancy-associated hypercalcemia |
Detects occult metastatic disease |
|
Skeletal survey |
Suspected multiple myeloma |
Detects lytic bone lesions |
|
Bone scan |
Suspected metastatic bone disease |
Identifies osteolytic metastases |
|
Renal ultrasonography |
Renal symptoms or longstanding hypercalcemia |
Detects nephrolithiasis and nephrocalcinosis |
|
DEXA scan |
Primary hyperparathyroidism |
Evaluates osteoporosis and fracture risk |
|
Parathyroid ultrasound |
Confirmed primary hyperparathyroidism before surgery |
Localizes parathyroid adenoma |
|
Sestamibi scan |
Preoperative localization in PHPT |
Identifies hyperfunctioning parathyroid tissue |
|
Genetic testing for CaSR mutation |
Strong suspicion of FHH |
Confirms familial hypocalciuric hypercalcemia |
|
Serum vitamin A level |
Excess supplement use suspected |
Hypervitaminosis A can cause hypercalcemia |
|
Serum cortisol and catecholamines |
MEN syndrome suspicion |
Evaluates endocrine neoplasia syndromes |
|
TB testing (IGRA/AFB studies) |
Suspected tuberculosis |
TB can cause calcitriol-mediated hypercalcemia |
|
Fungal serology |
Endemic fungal exposure with granulomatous disease |
Detects fungal causes of calcitriol-mediated hypercalcemia |
|
Medication review |
In every patient |
Identifies thiazides, lithium, vitamin D, calcium supplements, vitamin A, teriparatide, antacids |
|
Urinalysis |
Renal symptoms or stones |
Detects hematuria, crystals, renal injury |
|
Arterial blood gas |
Critically ill or alkalosis suspected |
Evaluates acid-base status affecting calcium binding |
|
Serum osmolality |
Severe dehydration or altered sensorium |
Assesses dehydration severity |
|
Step |
Investigation |
Why |
|
1 |
Confirm calcium + albumin |
Ensure true hypercalcemia |
|
2 |
Ionized calcium |
Confirm physiologic hypercalcemia |
|
3 |
PTH |
Most important categorization test |
|
4 |
If PTH high/normal → urinary calcium + CCCR |
Differentiate PHPT vs FHH |
|
5 |
If PTH suppressed → PTHrP, vitamin D metabolites, SPEP/UPEP |
Search for malignancy/vitamin D causes |
|
6 |
Imaging guided by suspicion |
Identify source disease |
Pattern Recognition Table
|
Finding |
Likely Cause |
|
High PTH + low phosphate |
Primary hyperparathyroidism |
|
High PTH + CKD |
Tertiary HPT |
|
Low PTH + high PTHrP |
Malignancy |
|
Low PTH + high 25-OH D |
Vitamin D intoxication |
|
Low PTH + high 1,25-OH₂ D |
Sarcoidosis/lymphoma |
|
Low urine calcium |
FHH |
|
Hypercalcemia + lytic lesions |
Myeloma/metastases |
|
Hypercalcemia + alkalosis + AKI |
Milk-alkali syndrome |
Management of Hypercalcemia
Indications for Immediate Treatment
- Serum calcium ≥14 mg/dL
- Symptomatic hypercalcemia
- Neurologic symptoms
- ECG changes
- Acute kidney injury
- Severe dehydration
- Pancreatitis
- Hypercalcemic crisis
- Rapidly rising calcium
Treatment Based on Severity
|
Severity |
Treatment |
|
Mild asymptomatic |
Treat cause, hydration |
|
Moderate symptomatic |
IV saline ± calcitonin |
|
Severe (>14 mg/dL) |
Saline + calcitonin + bisphosphonate |
|
Refractory |
Denosumab/dialysis |
1. Volume Resuscitation
Most important initial therapy.
Fluid-Isotonic saline
Mechanism:
- Corrects dehydration
- Enhances calciuresis
Typical Regimen
- Initial bolus:
- 1–2 L over first 1–2 hours if hypovolemic
- Maintenance:
- 200–300 mL/hr
- Adjust to:
- Urine output: 100–150 mL/hr
- Clinical status
Special Situations
Heart Failure
- Slower infusion
- Hemodynamic monitoring
- May require loop diuretic
CKD
- Careful hydration
- Frequent reassessment
Pharmacologic Therapy
1. Calcitonin
Mechanism
- Inhibits osteoclasts
- Increases renal calcium excretion
Dose
Calcitonin=4 IU/kg SC/IM every 12 hours
Can increase to:
- 8 IU/kg every 6 hours
Onset
- 4–6 hours
Duration
- Tachyphylaxis after 48 hours -Used as bridge therapy
2. Bisphosphonates
Mainstay for malignancy-associated hypercalcemia.
Mechanism
- Inhibit osteoclast-mediated bone resorption
Zoledronic Acid
|
Parameter |
Details |
|
Dose |
4 mg IV |
|
Infusion time |
Over ≥15 min |
|
Onset |
24–48 hr |
|
Peak effect |
4–7 days |
|
Duration |
Weeks |
2. Pamidronate
|
Parameter |
Details |
|
Dose |
60–90 mg IV |
|
Infusion |
Over 2–6 hr |
|
Onset |
24–48 hr |
3. Denosumab
Useful in:
- Refractory hypercalcemia
- Severe renal failure
- Bisphosphonate-resistant disease
Mechanism:
- RANKL inhibitor
Dose:
- 120 mg SC
Typically:
- Day 1
- Day 8
- Day 15
- Then monthly
4. Glucocorticoids
Best for:
- Vitamin D-mediated hypercalcemia
- Sarcoidosis
- Lymphoma
|
Drug |
Dose |
|
Prednisone |
40–60 mg/day |
|
Hydrocortisone |
200–300 mg/day IV |
Mechanism:
- Reduce calcitriol production
5. Loop Diuretics
Not routinely recommended initially.
Use ONLY:
- After adequate hydration
- If fluid overload develops
Example:
- Furosemide -20–40 mg IV
6. Dialysis
Indications:
- Severe refractory hypercalcemia
- Renal failure
- Heart failure
- Life-threatening arrhythmias
- Unable to tolerate fluids
Use:
- Low-calcium dialysate
